catalyst calendar
CYBIN INC · Data as of 2026-10-25
Q4 2026
The Company reiterated that HLP003 APPROACH Phase 3 topline data readout is on track for Q4 2026 1,2 and provided an overview of the competitive landscape and commercial opportunity in the adjunctive treatment of MDD.Source filing
Jun 30
Each Warrant will be exercisable to acquire one Common Share at a price of US$8.14 per Common Share at any time prior to the earlier of: (i) June 30, 2027; (ii) thirty days following the publication by press release of topline data for the APPROACH trial of CYB003 in major depressive disorder; and (iii) thirty days following the date a press release is issued by the Company announcing exercise of its acceleration right, which right can only be exercised if the closing price of the Common Share on NYSE American LLC (the " NYSE American ") is equal to or exceeds US$19.53 per Common Share for any five consecutive trading days.Source filing
in 2028
Helus Pharma expects to file a New Drug Application with the FDA in 2028. 1,2Source filing